1Frielle T,Ikegami H,Daniel KW,et al.Cloning of the cDNA for the human β1-adrenergic receptor.Proc Natl Acad Sci USA,1987,84:7920-7924.
2Maqbool A,Hall AS,Balmforth AJ,et al.Common polymorphisms of theβ1-agrenoceptor:identification and rapid screening assay.Lancet,1999,353:897.
3Moore JD,Mason DA,Green SA,et al.Racial differences in the frequencies of cardiac β1-adrenergic receptor polymorphisms:analysis of c145A→G and c1165G→C.Human Mutation,1999,14:271.
4Johnson JA,Terra SG.β-adrenergic receptor polymorphisms:cardiovascular disease associations and pharmacogenetics.Pharm Res,2002,19:1779-1787.
5Johnson JA,Zineh I,Puckett BJ,et al.β1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.Clin Pharmacol Ther,2003,74:44-52.
6Podlowski S,Wenzel K,Luther HP,et al.β1-adrenoceptor gene variations:a role in idiopathic dilated cardiomyopathy?J Mol Med,2000,78:87-93.
7Rathz DA,Brown KM,Kramer LA,et al.Amino acid 49 polymorphism of the human β1-adrenergic receptor affect agonist-promoted trafficking.J Cardiovasc Pharmacol,2002,39:155-160.
8Levin MC,Marullo S,Muntaner O,et al.The myocardium-protective Gly-49 variant of the β1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation.J Biol Chem,2002,277:30429-30435.
9Mason DA,Moore JD,Green SA,et al.A gain of function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor.J Biol Chem,1999,274:12670-12674.
10Sandilands AJ,Yeo G,Brown MJ,et al.Functional responses of human β1 adrenoceptors with defined haplotypes for the common 389R＞G and 49S＞G polymorphisms.Pharmacogenetics,2004,14:343-349.
5Ovaska H, Ludman A, Spencer EP, et al. Propafenone poisoning-a case report with plasma propafenone concentrations[J]. J Med Toxicol, 2010, 6(1):37-40.
6Magnus IS, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects[J]. Pharmacol Ther, 2007, 116(3) : 496-526.
7Taguehi M, Nozawa T, Kameyama T, et al. Effect of CYP2D6* 10 on pbarmaeokinetic variability of routinely administered metoprolol in middle aged and elderly Japanese patients[J]. Eur J Clin Pbar macol, 2003, 59(5/6): 385-388.
8Sharp CF, Gardiner SJ, Jensen BP, et al. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure CYP2D6, metoprolol and heart failure [J]. Pharmacogenomics J, 2009, 9(3): 175-184.
9Chen B, Cai WM. Influence of CYP2D6 ^+ 10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects[J].Acta Pharmacol Sin, 2003, 24(12):1277-1280.
10Sheffield LJ, Phillimore HE. CYP3A4 is the most abundant enzyme and is associated with metabolism of about 50% of drugs in clinical use[J]. Clin Bio chem Rev, 2009, 30(2): 55-65.
